FICHIT

Je m'inscris

BIOPHYTIS

0/5 (0 note(s))
Note donnée : aucune
Paris
43
Oganic health ingredients as dietary supplements and functional food products for metabolic disorders and age-related diseases.
The most advanced of the Biophytis programmes are aimed at Sarcopenia and Armd :
In sarcopenia, the SARCOB technological platform combines the candidates BIO101 and BIO103.
In ARMD, the MACULIA technological platform MACULIA combines the candidates BIO201 and BIO203.
The candidates BIO101 and BIO201, derived from natural molecules, are entering Phase 2B clinical development
The candidates BIO201 and BIO203, molecules derived from the hemisynthesis of natural substances, are in the pre-clinical phase and should be entering regulatory studies on humans during 2016
VEILLET Stanislas
www.biophytis.com
ALBPS:FP

Fiche créée le 10/04/2016 par Guillaume   vue 20 fois.